Polyclonal allergen-specific immunoglobulin E and adaptive immune system components (IgE/AIS)

Polyclonal allergen-specific immunoglobulin E (IgE) and the broader adaptive immune system components constitute the primary pathway for allergic sensitization and chronic inflammatory responses in atopic diseases. IgE is a specialized antibody isotype produced by B cells in response to allergens, which then binds to high-affinity FcεRI receptors on the surface of mast cells and basophils (Source: UniProt, P01854). Upon subsequent allergen exposure, cross-linking of these IgE-receptor complexes triggers the immediate release of inflammatory mediators like histamine, while the broader adaptive immune system, particularly Th2 cells, sustains the response through the secretion of cytokines such as IL-4, IL-5, and IL-13 (Source: NIH, StatPearls). These cytokines drive further IgE production and the recruitment of eosinophils, contributing to the pathophysiology of diseases like asthma, allergic rhinitis, and atopic dermatitis. Therapeutic strategies targeting this system include monoclonal antibodies that neutralize circulating IgE, such as omalizumab, or those that block cytokine signaling, such as dupilumab (Source: FDA, Xolair and Dupixent Labels). Because this entry encompasses a wide array of antibodies, cell types, and signaling molecules, it is classified as a physiological pathway or system rather than a single discrete molecular target.

Other names

Allergen-specific IgEType I hypersensitivity pathwayAdaptive immune systemTh2-mediated immune response

Therapeutic strategies involve the neutralization of circulating IgE to prevent binding to high-affinity FcεRI receptors (Source: PubMed, PMID: 24507024), the inhibition of Th2-type cytokines like IL-4 and IL-13 to prevent IgE class switching (Source: NIH, StatPearls), and the depletion of eosinophils via IL-5 antagonism (Source: Nature Reviews Drug Discovery).